479 related articles for article (PubMed ID: 33417831)
21. DNA repair gene expression is increased in HPV positive head and neck squamous cell carcinomas.
Holcomb AJ; Brown L; Tawfik O; Madan R; Shnayder Y; Thomas SM; Wallace NA
Virology; 2020 Sep; 548():174-181. PubMed ID: 32838940
[TBL] [Abstract][Full Text] [Related]
22. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
[TBL] [Abstract][Full Text] [Related]
23. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
24. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus and gene mutations in head and neck squamous carcinomas.
Friedland P; Thomas A; Naran A; Amanuel B; Grieu-Iacopetta F; Carrello A; Harnett G; Meyer C; Phillips M
ANZ J Surg; 2012 May; 82(5):362-6. PubMed ID: 22507644
[TBL] [Abstract][Full Text] [Related]
26. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
[TBL] [Abstract][Full Text] [Related]
27. Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
Lee DJ; Eun YG; Rho YS; Kim EH; Yim SY; Kang SH; Sohn BH; Kwon GH; Lee JS
Oral Oncol; 2018 Oct; 85():44-51. PubMed ID: 30220319
[TBL] [Abstract][Full Text] [Related]
28. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
30. Somatic 9p24.1 alterations in HPV
Zhao X; Cohen EEW; William WN; Bianchi JJ; Abraham JP; Magee D; Spetzler DB; Gutkind JS; Alexandrov LB; Cavenee WK; Lippman SM; Davoli T
Proc Natl Acad Sci U S A; 2022 Nov; 119(47):e2213835119. PubMed ID: 36395141
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab for the treatment of head and neck squamous cell cancer.
Ho WJ; Mehra R
Expert Opin Biol Ther; 2019 Sep; 19(9):879-885. PubMed ID: 31317798
[No Abstract] [Full Text] [Related]
32. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Kao HF; Lou PJ
Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Sacco AG; Chen R; Worden FP; Wong DJL; Adkins D; Swiecicki P; Chai-Ho W; Oppelt P; Ghosh D; Bykowski J; Molinolo A; Pittman E; Estrada MV; Gold K; Daniels G; Lippman SM; Natsuhara A; Messer K; Cohen EEW
Lancet Oncol; 2021 Jun; 22(6):883-892. PubMed ID: 33989559
[TBL] [Abstract][Full Text] [Related]
34. Impact of age on the overall survival benefits of anti-EGFR-containing regimens in head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials.
Zhao Y; Liu W; Sun M; Miao Q; Liu Y; Tian H; Su Y; Han F
Crit Rev Oncol Hematol; 2019 Mar; 135():39-46. PubMed ID: 30819445
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
36. Tumor-Specific Antibody, Cetuximab, Enhances the
Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
Front Immunol; 2020; 11():591139. PubMed ID: 33281820
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Segal NH; Ou SI; Balmanoukian A; Fury MG; Massarelli E; Brahmer JR; Weiss J; Schöffski P; Antonia SJ; Massard C; Zandberg DP; Khleif SN; Xiao F; Rebelatto MC; Steele KE; Robbins PB; Angra N; Song X; Abdullah S; Butler M
Eur J Cancer; 2019 Mar; 109():154-161. PubMed ID: 30731276
[TBL] [Abstract][Full Text] [Related]
38. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
39. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
